- Home
- CCK vs ROIV Comparison
CCK vs ROIV Comparison
Compare CCK & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCK
- ROIV
- Stock Information
- Founded
- CCK 1906
- ROIV 2014
- Country
- CCK United States
- ROIV United Kingdom
- Employees
- CCK N/A
- ROIV N/A
- Industry
- CCK Containers/Packaging
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CCK Industrials
- ROIV Health Care
- Exchange
- CCK Nasdaq
- ROIV Nasdaq
- Market Cap
- CCK 10.4B
- ROIV 8.4B
- IPO Year
- CCK N/A
- ROIV N/A
- Fundamental
- Price
- CCK $85.14
- ROIV $10.15
- Analyst Decision
- CCK Strong Buy
- ROIV Buy
- Analyst Count
- CCK 13
- ROIV 4
- Target Price
- CCK $104.85
- ROIV $17.50
- AVG Volume (30 Days)
- CCK 1.4M
- ROIV 8.0M
- Earning Date
- CCK 04-28-2025
- ROIV 05-29-2025
- Dividend Yield
- CCK 1.22%
- ROIV N/A
- EPS Growth
- CCK N/A
- ROIV N/A
- EPS
- CCK 3.55
- ROIV N/A
- Revenue
- CCK $11,801,000,000.00
- ROIV $122,585,000.00
- Revenue This Year
- CCK $2.52
- ROIV N/A
- Revenue Next Year
- CCK $2.51
- ROIV N/A
- P/E Ratio
- CCK $23.98
- ROIV N/A
- Revenue Growth
- CCK N/A
- ROIV 140.04
- 52 Week Low
- CCK $70.84
- ROIV $8.73
- 52 Week High
- CCK $98.46
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- CCK 47.74
- ROIV 50.07
- Support Level
- CCK $83.51
- ROIV $9.90
- Resistance Level
- CCK $86.49
- ROIV $10.26
- Average True Range (ATR)
- CCK 3.40
- ROIV 0.47
- MACD
- CCK -0.03
- ROIV 0.06
- Stochastic Oscillator
- CCK 62.31
- ROIV 92.81
About CCK Crown Holdings Inc.
Crown Holdings is one of the world's largest producers of metal packaging. The company manufactures beverage cans, metal food cans, and closures as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.